Showing results (801-810 of 827) with videos related to

Sort By:
Pageof 83
Blood Cancer Journal|March 13, 2026
Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus ClassificationWan-Hsuan Lee, Hsin-An Hou, Chien-Chin Lin, et al.
Blood Cancer Journal|April 9, 2024
Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasmsWan-Hsuan Lee, Chien-Chin Lin, Cheng-Hong Tsai, et al.
European Heart Journal|September 10, 2021
Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide studyXin Jiang, Yong-Jian Zhu, Yu-Ping Zhou, et al.
Blood Research|December 26, 2025
Prognostic impact of lymphocyte to monocyte ratio in patients with myelodysplastic neoplasms/syndromesWan-Hsuan Lee, Chien-Chin Lin, Xavier Cheng-Hong Tsai, et al.
Neurosurgery|November 24, 2025
Combination of Neuronavigation-Guided Focused Ultrasound and Bevacizumab for Patients With Recurrent Glioblastoma: A Pilot StudyKo-Ting Chen, Hong-Chieh Tsai, Chiung-Yin Huang, et al.
Ebiomedicine|October 27, 2018
Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndromeBor-Sheng Ko, Yu-Fen Wang, Jeng-Lin Li, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 30, 2025
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World AnalysisTai-Chung Tseng, Yu-Sung Chang, Xavier Cheng-Hong Tsai, et al.
Blood Cancer Journal|September 8, 2018
GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemiaFeng-Ming Tien, Hsin-An Hou, Cheng-Hong Tsai, et al.
American Journal of Hematology|March 2, 2023
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemiaMin-Yen Lo, Xavier Cheng-Hong Tsai, Chien-Chin Lin, et al.
Blood Cancer Journal|May 19, 2025
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutationsSao-Chih Ni, Chi-Yuan Yao, Xavier Cheng-Hong Tsai, et al.
Pageof 83